Cardiac Safety of Indacaterol

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers, Chronic Obstructive Pulmonary Disease

In brief

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Key facts

Study ID

NCT01263808

Run by

Novartis Pharmaceuticals

People needed

404

Starts

2008-04-01

Last updated by the study team

2010-12-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, non-smoking
• Body mass index (BMI) 18.5-32 kg/m2
• Body weight at least 50 kg

You may not qualify if…

• Recent/concurrent use of concomitant medications (except acetaminophen)
• Recent participation in other clinical trials
• Recent donation or loss of blood
• History/presence of a range of medical conditions, including electrocardiographic (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis investigative site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.